Philippe MARC

Connecting biology data since 1998. Currently at Novartis.

[Fiona Marshall @FionaHMarshall]

This is an exciting opportunity to learn from brilliant mentors while applying your AI and #datascience skills in the field of drug discovery. Recent PhD graduates are encouraged to apply by July 29. https://t.co/0FANLm0EFG

[Bruce Booth @LifeSciVC]

Fundraising by VCs was very strong in 2023, raising $19B for health-related funds. In past three years, ~$70B in new funds were raised.

That's a TON of "dry powder" that will get put to work into startups over the next 2-5 years

#SVBHealthcare @SiliconVlyBank #biotech

[Kazz🇨🇦 @KazzBio]

Predictions of What We Expect in 2024 in M&A
pharmas expected to have “high” or “very high” M&A appetite in 2024.
M&A interest is expected to be highest in cardiometabolic disease, immunology, oncology, genetic disease and neurologic diseases.
From Stifel
wowowow $XBI

[Philippe MARC @PMarcAtWork]

Will we finally stop the pollution of scientific knowledge by #FakePapers from #PaperMills?
Fake Publications in Biomedical Science: Red-flagging Method Indicates Mass Production https://t.co/oRUp10D2xJ

[Philippe MARC @PMarcAtWork]

Great discussion at #MedidataNext about partnering to innovate faster together and then run better clinical trials as a global community. Thx Xavier Briand , Martin Roche and Peter Buckman https://t.co/hHpGIQ52Uk

[Philippe MARC @PMarcAtWork]

#FDA reviewing #ML #AI use for #DrugDevelopment (section II), and articulating main questions we need to discuss (section III). Great read! https://t.co/64TDeevNN9

[Philippe MARC @PMarcAtWork]

Are #Pharma working on same #DrugTargets? According to McKinsey colleagues, oncology has 5x more projects per target since 2000! #NewModalities driven? or global R&D funding raising? Sup table 1 is a nice view of past “fashions” https://t.co/mlQBf9Hkxp

[Philippe MARC @PMarcAtWork]

A crowdsourced #benchmarking of US #biotech #compensation. Benchmark data are used everywhere, but rarely made public. Interesting move by @pillar-vc et al! https://t.co/Y8pAnJyYHE

[Philippe MARC @PMarcAtWork]

2022 #R&D #budget and highlights of #BigPharmas . Bottomline: investment in #innovation is very high, expectations also! It is hard to compare pure drug hunters to companies developing devices/diagnostic, but the overview is instructive. https://t.co/JoCuu5hcu8

[Philippe MARC @PMarcAtWork]

Measuring #aging via #epigenetics is known to be possible, but I found that paper really interesting to read. It is really integrating many biological questions and considerations #centenarian #clock https://t.co/9UpKnSgWCT

[Philippe MARC @PMarcAtWork]

Students and usage of #GPT, #LLM, #ChatGPT: an opportunity or a danger?
https://t.co/9IZmXCOF1s

[Philippe MARC @PMarcAtWork]

Delisting from #WebofScience of #IJERPH, one of the most prolific scientific journals. No #ImpactFactor anymore and probably a Oncotarget like future.

Great view on #MegaJournals: https://t.co/OanjAs1U6P

[Philippe MARC @PMarcAtWork]

A great way to discover #DataScience applications to a #pharma #researchanddevelopment. Come and join us! https://t.co/mMDYPdvAYC

[Philippe MARC @PMarcAtWork]

Drug sales in 2027 could be 1.9 Trillions + 0.5 T for Covid19 (Mullard, cf below). 2022 was ~1.5 T, 2014 was ~1T. Indicators are showing improvement of worldwide health, but the number is mind-blowing and also not evenly localised… #drugs #healthcost https://t.co/kMDBp3IpuI

[Philippe MARC @PMarcAtWork]

Nice review of emerging trends in #PreclinicalSafety by Francois Pognan et al #drugdevelopment #toxicology #gamechangers https://t.co/6cqicyfUug

[Philippe MARC @PMarcAtWork]

#Amazon #RxPass Prime at 5$! The US #drugmarket is complex with many players contributing to the
final drug price. Recently low-cost drugs are more directly available and affordable. #Renee.com, now #Amazon. That will help many! #generics https://t.co/qNZkXJwHSU

[Philippe MARC @PMarcAtWork]

Interesting view on #JPM2023 and where the #Pharma #Biotech industry stands 🤔 #deals #M&A #valuation #IRA https://t.co/UNOIbdCUra

[Philippe MARC @PMarcAtWork]

A view of #Biotech #IPOs in US over time. As expected 2022 was tough: number divided by 5 and total proceeds divided by 7. Still mostly small molecules, contrasting with #FDA's 2022 approval of 57% of #LMW. Onc and CNS as lead indications as in 2021.
2022…https://t.co/JaMUv7EYSw

[Nature Reviews Drug Discovery @NatRevDrugDisc]

2022 FDA approvals https://t.co/kPm9INJa6Z

The FDA approved 37 novel drugs in 2022 - here's the full list as part of our annual article by @AsherMullard, including trends and analysis of some of the key approvals

[Philippe MARC @PMarcAtWork]

Just seen those T characters used as error bars in a publication OMG! Funnier to me than the #BMJ Christmas issue this year!
#statistics #errorbars
https://t.co/poQCjvr3Xp https://t.co/pclH7p8aCo